Opportunity to invest in Canadian health science firm pioneering innovative treatments for breast cancer is now open globally to eligible investors. SAN FRANCISCO, OCTOBER 2023 – US Capital Global Securities LLC, an affiliate of US Capital Global, recently launched an investment opportunity of up to $5 million in Canadian health
Life Sciences Review has awarded Andira Pharmaceuticals the Top Therapeutic & Medical Device Products Provider 2023, and feature Andira in the August 17, 2023 issue with CEO, Dana Lambert, PhD on the cover. The article written by Jeremy Williams, begins, “The healthcare sector eagerly anticipates the next chapter of innovation
Opportunity to invest in Canadian health science firm pioneering a new generation of patented therapeutics for drug-resistant infection is now open globally to eligible investors. SAN FRANCISCO, AUGUST 2023 – US Capital Global Securities LLC, an affiliate of US Capital Global, recently launched an investment opportunity of up to $5
Through a Collaborative Research Agreement with Canada Research Chair in Oncology Dr. Karla Williams at the University of British Columbia Vancouver, British Columbia, Canada–Andira Pharmaceuticals announces it will carry out pharmacologic characterization of its lead compounds for metastatic breast cancer through a collaborative research program with the University of British
Vancouver, British Columbia, Canada– Andira Pharmaceuticals is proud to welcome Janette Lyons as Chief Financial Officer (CFO). Janette is a senior finance and business leader with over 15 years of executive financial management experience. She brings to Andira an impressive track record of success working in start-ups, multinational, crown corporation,
Andira CEO Dana Lambert, PhD says, “I wanted to take the opportunity to recognize Dr. Claudia Dietrich and her outstanding achievements as a research scientist on our team. She is a talented and highly motivated professional and has been a driving force behind the successful development of our wound care
VANCOUVER, BC, May 31, 2022 – Andira Pharmaceuticals is proud to announce the hiring of Eurofins Discovery to conduct pre-clinical research on Andira’s lead asset, a cannabinoid-based injectable antibiotic for treatment of hospital-acquired infection. Eurofins Discovery is the leading contract research organization (CRO) brand with over 35 years of success
Vancouver, BC – Andira Pharmaceuticals is pleased to welcome Ryan Miller to the Advisory Board. Mr. Miller is a finance veteran with over 15 years of experience in Corporate Finance, Technology, and Energy. After serving as CFO and VP of Finance for several large Canadian companies, Mr. Miller started his
Vancouver, BC Canada – Andira Pharmaceuticals is pleased to announce it has retained MCRA LLC, a world leading global medical device, regulatory and clinical research consulting firm based in Washington, DC, to consult and provide guidance during the regulatory approval process for its anti-microbial wound care adhesive which offers significantly
Vancouver, July 8, 2021– Andira Pharmaceuticals (“Andira”) has been awarded two consecutive Mitacs Accelerate Internship grants to advance anti-infective R&D within the Prof. Charles Thompson Laboratory at the University of British Columbia (UBC) Department of Microbiology and Immunology. Both Mitacs grants directly support Dr. Claudia Dietrich, a UBC research scientist,
Opportunity to invest in Canadian health science firm pioneering innovative treatments for breast cancer is now open globally to eligible investors. SAN FRANCISCO, OCTOBER 2023 – US Capital Global Securities LLC, an affiliate of US Capital Global, recently launched an investment opportunity of up to $5 million in Canadian health
Life Sciences Review has awarded Andira Pharmaceuticals the Top Therapeutic & Medical Device Products Provider 2023, and feature Andira in the August 17, 2023 issue with CEO, Dana Lambert, PhD on the cover. The article written by Jeremy Williams, begins, “The healthcare sector eagerly anticipates the next chapter of innovation
Opportunity to invest in Canadian health science firm pioneering a new generation of patented therapeutics for drug-resistant infection is now open globally to eligible investors. SAN FRANCISCO, AUGUST 2023 – US Capital Global Securities LLC, an affiliate of US Capital Global, recently launched an investment opportunity of up to $5
Through a Collaborative Research Agreement with Canada Research Chair in Oncology Dr. Karla Williams at the University of British Columbia Vancouver, British Columbia, Canada–Andira Pharmaceuticals announces it will carry out pharmacologic characterization of its lead compounds for metastatic breast cancer through a collaborative research program with the University of British
Vancouver, British Columbia, Canada– Andira Pharmaceuticals is proud to welcome Janette Lyons as Chief Financial Officer (CFO). Janette is a senior finance and business leader with over 15 years of executive financial management experience. She brings to Andira an impressive track record of success working in start-ups, multinational, crown corporation,
Andira CEO Dana Lambert, PhD says, “I wanted to take the opportunity to recognize Dr. Claudia Dietrich and her outstanding achievements as a research scientist on our team. She is a talented and highly motivated professional and has been a driving force behind the successful development of our wound care
VANCOUVER, BC, May 31, 2022 – Andira Pharmaceuticals is proud to announce the hiring of Eurofins Discovery to conduct pre-clinical research on Andira’s lead asset, a cannabinoid-based injectable antibiotic for treatment of hospital-acquired infection. Eurofins Discovery is the leading contract research organization (CRO) brand with over 35 years of success
Vancouver, BC – Andira Pharmaceuticals is pleased to welcome Ryan Miller to the Advisory Board. Mr. Miller is a finance veteran with over 15 years of experience in Corporate Finance, Technology, and Energy. After serving as CFO and VP of Finance for several large Canadian companies, Mr. Miller started his
Vancouver, BC Canada – Andira Pharmaceuticals is pleased to announce it has retained MCRA LLC, a world leading global medical device, regulatory and clinical research consulting firm based in Washington, DC, to consult and provide guidance during the regulatory approval process for its anti-microbial wound care adhesive which offers significantly
Vancouver, July 8, 2021– Andira Pharmaceuticals (“Andira”) has been awarded two consecutive Mitacs Accelerate Internship grants to advance anti-infective R&D within the Prof. Charles Thompson Laboratory at the University of British Columbia (UBC) Department of Microbiology and Immunology. Both Mitacs grants directly support Dr. Claudia Dietrich, a UBC research scientist,
Andira is a private healthcare company leveraging natural drug substances to improve lives and address critical illnesses. The company is advancing urgently needed solutions for highly prevalent medical indications in three areas: hospital acquired infection, oncology and dermatology.
Join our mailing list for our periodic general business, fundraising and scientific updates.
Copyright © 2023 Andira Pharmaceuticals
